Nostrum Biodiscovery (NBD), a spin-off of the IRB Barcelona and the Barcelona Supercomputing Centre (BSC-CNS) and a CataloniaBio & HealthTech member, has appointed Ezequiel Mas del Molino as its new CEO. Mas replaces Robert Soliva, who is leaving the company to take on a new professional challenge.
Ezequiel Mas holds a PhD in Biomedicine from the University of Barcelona and an Executive MBA from the EAE Business School. His professional career combines research experience with the management and leadership of scientific projects, both in the industry (CIRCE Crystal Engineering) and public institutions (Leitat and BSC-CNS).
The company's activity focuses on speeding up emerging drug discovery and enzyme engineering projects, using a combination of cutting-edge bioinformatics tools. One of the latest projects is with Grifols, IrsiCaixa and the BSC-CNS, in which NBD collaborates by providing data that facilitates the smart, in silico design of SARS-CoV-2-related drugs.
NBD currently has a broad and highly stable portfolio of clients in the United Kingdom, Belgium, the Netherlands, Sweden and the United States. "Our short-term objective is to consolidate our presence in the European and American markets, and to break into the Asian markets," explains Ezequiel Mas. For the period 2016 to 2019, the company had a turnover of €1.1M.
Foto: Ezequiel Mas at NBD headquarters located at the Barcelona Science Park.
Comments